Skip to main content

Research Repository

Advanced Search

Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer

Perks, Claire M.; Holly, Jeff M.P.; Koobotse, Moses O.; Dean, Sarah J; Bhoo-Pathy, Nirmala; Looi, Lai Meng; Mohammed, Nur Aishah Taib; Mun, Kein Seong; Teo, Soo Hwang; Yip, Cheng Har; Rhodes, Anthony

Authors

Claire M. Perks

Jeff M.P. Holly

Moses O. Koobotse

Sarah Dean Sarah4.Dean@uwe.ac.uk
Senior Lecturer in Biomedical Science

Nirmala Bhoo-Pathy

Lai Meng Looi

Nur Aishah Taib Mohammed

Kein Seong Mun

Soo Hwang Teo

Cheng Har Yip

Anthony Rhodes



Abstract

© American Society for Clinical Pathology. Objectives: To investigate the association between PTEN loss and IGFBP2 expression in a series of triple-negative breast cancers and to relate this expression to basal cytokeratin expression and clinicopathologic features. Methods: One hundred and one formalin-fixed and paraffin-processed triple-negative breast cancer cases from the University of Malaya Medical Centre were tested immunohistochemically for cytokeratins 5/6 and 14, PTEN, and IGFBP2. The resulting slides were scored for proportion and intensity of staining. Results: Loss of tumor nuclear and cytoplasmic staining for PTEN occurred in 48.3% of cases and was significantly associated with younger age at diagnosis (47 years compared with 57 years in those without PTEN loss; P = .005). Independent predictors of PTEN loss were late stage at presentation ( P = .026), cytokeratin 5/6 positivity ( P = .028), and IGFBP2 expression ( P = .042). High levels of IGFBP2 expression were seen in 32% of cases; an independent predictor of high levels was cytokeratin 14 negativity ( P = .005). PTEN loss and high levels of IGFBP2 expression were associated with poorer survival, but neither of these trends was significant. Conclusions: PTEN loss is a frequent event in triple-negative breast cancers and is significantly associated with younger age at onset of breast cancer, late stage, and IGFBP2 expression.

Journal Article Type Article
Publication Date Mar 1, 2014
Journal American Journal of Clinical Pathology
Print ISSN 1943-7722
Electronic ISSN 1943-7722
Publisher Oxford University Press (OUP)
Peer Reviewed Peer Reviewed
Volume 141
Issue 3
Pages 323-333
APA6 Citation Koobotse, M. O., Holly, J. M., Perks, C. M., Dean, S. J., Dean, S. J., Perks, C., …Rhodes, A. (2014). Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. American Journal of Clinical Pathology, 141(3), 323-333. https://doi.org/10.1309/AJCPR11DEAYPTUSL
DOI https://doi.org/10.1309/AJCPR11DEAYPTUSL
Keywords PTEN, IGFBP2, triple-negative breast cancer
Publisher URL http://dx.doi.org/10.1309/AJCPR11DEAYPTUSL
Additional Information Additional Information : This is a pre-copyedited, author-produced PDF of an article accepted for publication in American Journal of Clinical Pathology following peer review. The version of record Dean, S., Perks, C., Holly, J., Bhoo-Pathy, N., Looi, L.-M., Mohammed, N. A. T., Mun, K.-S., Teo, S.-H., Koobotse, M., Yip, C.-H. and Rhodes, A. (2014) Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. American Journal of Clinical Pathology, 141 (3). pp. 323-333 is available online at: http://dx.doi.org/10.1309/AJCPR11DEAYPTUSL

Files








You might also like



Downloadable Citations

;